Press Releases

Press Releases

Business Wire | March 08, 2018
Research presented at Conference on Retroviruses and Opportunistic Infections (CROI) validates platform’s advanced detection capabilities and demonstrates potential to detect the infection at pre-symptomatic stages
Business Wire | March 07, 2018
Quanterix announced that it will release its financial results for fourth quarter and fiscal year 2017 after the close of trading on Wednesday, March 14, 2018.
Business Wire | March 07, 2018
Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at the Cowen and Company 38th Annual Healthcare Conference, on Monday, March 12, 2018 at 4:50 p.m., EST at the Boston Marriott Copley Place.
Business Wire | February 08, 2018
Chief Executive Officer, President and Chairman, Kevin Hrusovsky, will be presenting at the LEERINK Partners 7th Annual Global Healthcare Summit. The presentation will take place on Thursday, February 15, at 10:00 a.m. EST in New York City.
Business Wire | January 04, 2018
Chief Executive Officer, President and Chairman, Kevin Hrusovsky, will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference.
Business Wire | January 02, 2018
Ultra-Sensitive Biomarker Detection System is now available in a compact size with increased workflow flexibility
BusinessWire | December 11, 2017
Quanterix Corporation (NASDAQ:QTRX), a company with a next generation, ultra-sensitive digital platform that advances precision health, today announced the closing of its initial public offering of 4,916,480 shares of common stock at a public offering price of $15.00 per share, including 641,280…
Nasdaq | December 07, 2017
Quanterix Corporation (Nasdaq:QTRX), a company with a next generation, ultra-sensitive digital platform that advances precision health, will visit the Nasdaq MarketSite in Times Square.
Business Wire | December 06, 2017
Today Quanterix announced the pricing of its initial public offering of 4,275,200 shares of its common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $64,128,000. In addition, Quanterix has granted the underwriters a 30-day option to purchase up to 641,280…
Business Wire | November 10, 2017
New technology unlocks ultra-sensitive biomarker detection with the potential to advance the diagnosis and treatment of neurological diseases